BAFF 与自身反应性 B 细胞的选择。
BAFF and selection of autoreactive B cells.
机构信息
Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, New York, NY 11030, USA.
出版信息
Trends Immunol. 2011 Aug;32(8):388-94. doi: 10.1016/j.it.2011.06.004. Epub 2011 Jul 13.
Abstract
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells, and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF inhibitor, belimumab, is the first new drug in 50 years to be approved for the treatment of SLE. However, the mechanism of action of this drug is not entirely clear. In this review we will focus on the role of the BAFF-APRIL signaling pathway in the selection of autoreactive B cells, and discuss whether altered selection is the mechanism for the therapeutic efficacy of BAFF inhibition in SLE.
摘要
B 细胞激活因子（BAFF）是过渡性和成熟 B 细胞的关键生存因子，是治疗系统性红斑狼疮（SLE）的有前途的治疗靶点。BAFF 抑制剂贝利尤单抗是 50 年来批准用于治疗 SLE 的第一种新药。然而，该药物的作用机制尚不完全清楚。在这篇综述中，我们将重点讨论 BAFF-APRIL 信号通路在自身反应性 B 细胞选择中的作用，并讨论改变选择是否是 BAFF 抑制治疗 SLE 疗效的机制。
相似文献
1
BAFF and selection of autoreactive B cells.
Trends Immunol. 2011 Aug;32(8):388-94. doi: 10.1016/j.it.2011.06.004. Epub 2011 Jul 13.
2
BAFF inhibition in SLE-Is tolerance restored?
Immunol Rev. 2019 Nov;292(1):102-119. doi: 10.1111/imr.12810. Epub 2019 Sep 28.
3
The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. doi: 10.1016/j.cytogfr.2013.04.003. Epub 2013 May 15.
4
The rationale for BAFF inhibition in systemic lupus erythematosus.
Curr Rheumatol Rep. 2012 Aug;14(4):295-302. doi: 10.1007/s11926-012-0258-2.
5
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
Expert Opin Ther Targets. 2014 Apr;18(4):473-89. doi: 10.1517/14728222.2014.888415. Epub 2014 Feb 13.
6
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Drug Des Devel Ther. 2015 Jan 7;9:333-47. doi: 10.2147/DDDT.S67264. eCollection 2015.
7
Targeting the BLyS-APRIL signaling pathway in SLE.
Clin Immunol. 2013 Sep;148(3):322-7. doi: 10.1016/j.clim.2012.11.010. Epub 2012 Dec 6.
8
B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
Int J Mol Sci. 2024 Oct 9;25(19):10845. doi: 10.3390/ijms251910845.
9
BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Immunol Cell Biol. 2012 Mar;90(3):293-303. doi: 10.1038/icb.2011.111. Epub 2012 Jan 10.
10
When to use belimumab in SLE.
Expert Rev Clin Immunol. 2017 Aug;13(8):737-740. doi: 10.1080/1744666X.2017.1324784. Epub 2017 May 5.
引用本文的文献
1
Conventional and non-conventional antigen-binding sites promote the development and function of chronic lymphocytic leukemia stereotyped subset #4 clones.
Front Immunol. 2025 Aug 21;16:1607189. doi: 10.3389/fimmu.2025.1607189. eCollection 2025.
2
BAFF and APRIL immunotherapy following Bacille Calmette-Guérin vaccination enhances protection against pulmonary tuberculosis in mice.
Front Immunol. 2025 Feb 6;16:1551183. doi: 10.3389/fimmu.2025.1551183. eCollection 2025.
3
The role of autoantibodies in bridging obesity, aging, and immunosenescence.
Immun Ageing. 2024 Nov 30;21(1):85. doi: 10.1186/s12979-024-00489-2.
4
The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae098.
5
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease.
RMD Open. 2024 Aug 28;10(3):e004112. doi: 10.1136/rmdopen-2024-004112.
6
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus.
Lupus Sci Med. 2023 Oct;10(2). doi: 10.1136/lupus-2023-000976.
7
Clinical research progress of novel biologics for the treatment of lupus nephritis.
Clin Exp Med. 2023 Dec;23(8):4153-4162. doi: 10.1007/s10238-023-01143-9. Epub 2023 Jul 22.
8
Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis.
Clin Exp Med. 2023 Nov;23(7):3011-3018. doi: 10.1007/s10238-023-01132-y. Epub 2023 Jul 18.
9
B cell activation via immunometabolism in systemic lupus erythematosus.
Front Immunol. 2023 May 15;14:1155421. doi: 10.3389/fimmu.2023.1155421. eCollection 2023.
10
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
Ren Fail. 2023 Dec;45(1):2207671. doi: 10.1080/0886022X.2023.2207671.
本文引用的文献
1
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
2
Current and novel therapeutics in the treatment of systemic lupus erythematosus.
J Allergy Clin Immunol. 2011 Feb;127(2):303-12; quiz 313-4. doi: 10.1016/j.jaci.2010.12.1087.
3
BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling.
J Immunol. 2010 Oct 15;185(8):4570-81. doi: 10.4049/jimmunol.1001708. Epub 2010 Sep 22.
4
Regulation of the B cell receptor repertoire and self-reactivity by BAFF.
J Immunol. 2010 Oct 1;185(7):4128-36. doi: 10.4049/jimmunol.1002176. Epub 2010 Sep 3.
5
B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor.
Immunol Rev. 2010 Sep;237(1):205-25. doi: 10.1111/j.1600-065X.2010.00944.x.
6
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88.
Nat Immunol. 2010 Sep;11(9):836-45. doi: 10.1038/ni.1914. Epub 2010 Aug 1.
7
Control systems and decision making for antibody production.
Nat Immunol. 2010 Aug;11(8):681-8. doi: 10.1038/ni.1900. Epub 2010 Jul 20.
8
Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.
J Exp Med. 2010 Aug 2;207(8):1757-73. doi: 10.1084/jem.20100086. Epub 2010 Jul 12.
9
Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling.
Immunity. 2010 Jun 25;32(6):778-89. doi: 10.1016/j.immuni.2010.06.006.
10
Primary antibody deficiency syndromes.
Curr Opin Hematol. 2010 Jul;17(4):356-61. doi: 10.1097/MOH.0b013e328338f69e.
Zotero 插件